I think the option to license the data for Lympro is being used to package Lympro for a private placement or under the best case scenario, possibly a partnership. They don't have any money to pay for the license until they get a funding, and they haven't even put together the lympro subsidiary yet. So they are sort of putting the cart before the horse. They can't finalize a negotiation at this point, because they don't have any funds to close on whatever deal they negotiate. They just have the data. So I assume whatever license they put together will be tied to some kind of funding/partnership they can create. I also think it's telling in the pr:

"prospective collaborators noted that what was missing from our initial dataset was the use of a reference standard that incorporated newly available biomarkers,"